INFECTIOUS DISEASE AEROBIOLOGY CORE

这个子项目是许多利用资源的研究子项目之一 由NIH/NCRR资助的中心拨款提供。次级项目的主要支助 子项目的主要研究者可能是由其他来源提供的， 包括其它NIH来源。 列出的子项目总成本可能 表示子项目使用的中心基础设施的估计数量， NCRR赠款不直接向子项目或子项目工作人员提供资金。 传染病空气生物学核心已成为TNPRC内的生产科学核心。 该核心扩大了生物气溶胶特性鉴定和各种传染性病原体气溶胶挑战所需的技术能力，增加了一个自动化版本的生物气溶胶暴露系统（2010年），并在坦桑尼亚国家生物安全中心校园内新的区域生物安全实验室的BSL-3信封内增加了空气生物学套件。 该核心还扩大了其功能能力，以提供干粉药用级治疗剂，并结合正在进行的药物评价研究，作为核心的一部分。 在大气生物学核心下运作的接触设施现在位于坦桑尼亚联合共和国防治荒漠化委员会批准的特定物剂登记生物安全3级（BSL-3）区域内的两个地点。 除了非人类灵长类动物气溶胶暴露能力外，该核心还对较小动物进行气溶胶暴露。 该核心的建立提供了独特的资源，使研究人员能够进行关键实验，以进一步了解空气传播传染病的生物学基础。 除了核心主任Chad J. Roy博士外，核心工作人员还包括全职研究科学家Satheesh Sivasubrahamni博士和核心气溶胶工程技术员Rachel Redmann女士。 在过去的一年中，核心一直从事合作研究与内部和NIH资助的校外研究人员;核心的校外用户的数量现在超过12个合作实验室。2010年，该中心使用以下病原体对93只个体非人灵长类动物进行了暴露：葡萄球菌肠毒素B（SE B）、蓖麻毒素、东方马脑炎病毒、类鼻疽伯克霍尔德氏菌、普氏立克次体、猴痘病毒、流感病毒和结核分枝杆菌。 该中心还进行了276次个体家兔暴露（96次个体感染和180次治疗性气雾剂处理）和168次啮齿动物暴露（128次感染和40次处理）。 除了动物暴露和治疗外，核心还对各种病原体和毒素以及治疗性生物制剂和药物进行了48次微生物表征评估。 过去一年的数据表明，大多数核心合作研究涉及实验性气溶胶感染，作为疾病模型开发或疫苗有效性等更广泛研究目标的重要组成部分。 除了实验性感染外，该核心还有助于为新型病原体（例如，RSV）和气溶胶活力评估。 要求使用新型微生物剂进行微生物效率研究（例如，裸DNA、伯克霍尔德氏菌属（Burkholderia sp.）随着合作实验室了解到通过该核心提供的能力，

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. The infectious disease aerobiology core has become a productive scientific core within the TNPRC. The core has expanded its technical capabilities required for bioaerosol characterization and aerosol challenge of diverse infectious agents by the addition of an automated version of the bioaerosol exposure system (in 2010) and the addition of the aerobiology suite within the BSL-3 envelope in the new regional biosafety laboratory on the campus of the TNRPC. The core has also expanded its functional capability to deliver dry powder pharmaceutical grade therapeutics in conjunction with drug evaluation studies that are ongoing as part of the core. The exposure facility operated under the aerobiology core is now located in two locations at the TNPRC within CDC-approved select agent registered biosafety level 3 (BSL-3) areas. In addition to nonhuman primate aerosol exposure capability, the core also performs aerosol exposures on smaller animals. Establishment of this core provides a unique resource that enables investigators to perform key experiments to further understand the biological basis of airborne-transmitted infectious diseases. In addition to the core director Dr. Chad J. Roy, the core is staffed by Dr. Satheesh Sivasubrahamni who serves as a fulltime research scientist and Ms. Rachel Redmann who serves as the core aerosol engineering technician. In the past year, the core has been consistently engaged in collaborative research studies with both intramural and NIH-funded extramural investigators; the number of extramural users of the core now exceeds twelve collaborating laboratories. In 2010, the core performed 93 individual nonhuman primate exposures using the following pathogens: staphylococcal enterotoxin B (SEB), ricin toxin, Eastern Equine Encephalitis virus, Burkholderia pseudomallei, Rickettsia prowazekii, monkeypox virus, influenza virus, and Mycobacterium tuberculosis. The core also performed 276 individual rabbit exposures (96 individual infections and 180 therapeutic aerosol treatments), and 168 rodent exposures (128 infections and 40 treatments). In addition to the animal exposures and treatments, the core performed 48 microbial characterization assessments with a variety of pathogenic organisms and toxins as well as therapeutic biologics and pharmaceuticals. Attested by the numbers shown for this past year, the majority of core collaborative research involves experimental aerosol infection as an essential component of studies broader research goals such as disease model development or vaccine efficacy. In addition to experimental infection, the core is instrumental in providing aerosol characterization for novel pathogenic agents (e.g., RSV) and aerosol viability assessment for viral-vectored vaccine products. Requests for microbial efficiency studies using novel microbial agents (e.g., naked DNA, Burkholderia sp.) have also continued to increase as collaborative laboratories learn of the capabilities made available through this core.